Cardiology

The randomized AWARE trial indicates patients with paroxysmal AF did not have improved freedom from recurrent atrial arrhythmia with a double ablation lesion set compared with a single procedure.

On March 24, the US Food and Drug Administration announced a proposed rule changes aimed at promoting use of safe and suitable salt substitutes with the intent of improving nutrition and reducing chronic illness.

Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments and payment per cardiologist.

Data from a meta-analysis show late gadolinium enhancement (LGE) on cardiac MRI scans and elevated fluorodeoxyglucose (FDG) uptake on PET scans are both strong predictors of major adverse cardiac events for cardiac sarcoidosis.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

An analysis of NHANES from 2013 - March 2020 suggest individuals with an indication for statin therapy for primary prevention based on 10-year risk saw low overall use across risk categories and race and ethnicity strata.

Released on March 21, the new scientific statement suggests supervised exercise training is safe and may offer substantial improvement in exercise capacity and quality of life, even more than medications, for many patients with heart failure.

A remote hypertension management program at Mass General Brigham was associated with significant improvements in blood pressure control despite systemic disruptions in care due to the COVID‐19 pandemic.

Children living in areas with greater neighborhood deprivation in the US have a higher likelihood of being diagnosed with primary hypertension, according to an analysis of more than 65,000 children.

This case report from Brady Pregerson, MD, features a woman in her late 60s with diabetes mellitus and hypertension presenting to the emergency department with 3 hours of chest heaviness, nausea, and lightheadedness. Can you determine the diagnosis?

New research from Intermountain Healthcare presented at ACC 2023 examines the prognostic value of disproportionate CAC scores for 1 or more vessels relative to the value of total CAC score for predicting major adverse cardiovascular events.

With ACC 2023 in the rearview, the HCPLive editorial team compiled perspectives on the meeting’s top piece of news from half a dozen clinicians specializing in various subspecialties across the spectrum of cardiovascular care.

Gregg W. Stone, MD, discussed the 5-year findings of the COAPT trial and provided insight into the benefit of the transcatheter procedure in high-risk patients with heart failure.

At ACC 2023, Hoeper provides insight into the key efficacy findings of STELLAR and delves into the safety concerns and generalizability of sotatercept for PAH.

An analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials provides insight into the atherosclerotic cardiovascular risk associated with high-sensitivity C-reactive protein.

In an interview at ACC 2023, Safia Chatur, MD provided insight into the analysis of the PARADIGM-HF and PARAGON-HF trials, suggesting early eGFR changes should not deter continuation of sacubitril/valsartan.

Deepak Bhatt, MD, MPH, discusses results of the phase 2 ENTRIGUE trial and how it informs clinicians on the effects of the human FGF21 analogue in patients with severe hypertriglyceridemia.

New research from a phase 2b trial presented at ACC 2023 suggests an oral PCSK9 inhibitor could help reduce LDL-C by 60% in patients with or at-risk for atherosclerotic cardiovascular disease.

Hear from Deepak Bhatt, MD, MPH, as he discusses how he interprets the results of the HALO trial and offers perspective on the forthcoming research related to baxdrostat.

At ACC 2023, results from the RAPID-HF trial reported atrial pacing was ineffective at improving exercise capacity in patients with HFpEF and chronotropic incompetence.

Results from the phase 3 A DUE study suggest a combination of macitentan and tadalafil nearly doubled reductions in pulmonary vascular resistance in patients with PAH.

Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.

Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints, including time to death or clinical worsening.

In an interview at ACC 2023, Ankeet Bhatt, MD, describes how virtual care team represents an effective and scalable approach to improve therapeutic optimization across a health system.

Data from COORDINATE-Diabetes presented at ACC 2023 demonstrate the impact of a multifaceted, coordinated care approach on improving prescription rates of statins, ACEs/ARBs, and glucose-lowering medications among people with type 2 diabetes.

In an interview at ACC 2023, Harrington elaborated on the upcoming phase 3 Librexia clinical trial program studying the Factor XIa inhibitor for the prevention of thrombotic events.

At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.

An interview with Dr. Annapoorna S. Kini at ACC 2023 breaks down the findings on the effect of evolocumab on coronary plaque characteristics in stable CAD from the YELLOW III study.

Steve Nissen, MD, sits down for an interview to discuss the clinical takeaways, design intricacies, safety signals, and more from the CLEAR Outcomes trial.

Implantation of a pacemaker to enhance exercise heart rate did not improve exercise capacity, symptoms, or exercise cardiac output in patients with HFpEF and chronotropic incompetence in the RAPID-HF trial.